Suppr超能文献

DNA复制应激介导乳腺癌中的载脂蛋白B编辑酶催化多肽样3(APOBEC3)家族诱变。

DNA replication stress mediates APOBEC3 family mutagenesis in breast cancer.

作者信息

Kanu Nnennaya, Cerone Maria Antonietta, Goh Gerald, Zalmas Lykourgos-Panagiotis, Bartkova Jirina, Dietzen Michelle, McGranahan Nicholas, Rogers Rebecca, Law Emily K, Gromova Irina, Kschischo Maik, Walton Michael I, Rossanese Olivia W, Bartek Jiri, Harris Reuben S, Venkatesan Subramanian, Swanton Charles

机构信息

UCL Cancer Institute, CRUK Lung Cancer Centre of Excellence, Paul O'Gorman Building, Huntley St., London, UK.

Translational Cancer Therapeutics Laboratory, The Francis Crick Institute, London, UK.

出版信息

Genome Biol. 2016 Sep 15;17(1):185. doi: 10.1186/s13059-016-1042-9.

Abstract

BACKGROUND

The APOBEC3 family of cytidine deaminases mutate the cancer genome in a range of cancer types. Although many studies have documented the downstream effects of APOBEC3 activity through next-generation sequencing, less is known about their upstream regulation. In this study, we sought to identify a molecular basis for APOBEC3 expression and activation.

RESULTS

HER2 amplification and PTEN loss promote DNA replication stress and APOBEC3B activity in vitro and correlate with APOBEC3 mutagenesis in vivo. HER2-enriched breast carcinomas display evidence of elevated levels of replication stress-associated DNA damage in vivo. Chemical and cytotoxic induction of replication stress, through aphidicolin, gemcitabine, camptothecin or hydroxyurea exposure, activates transcription of APOBEC3B via an ATR/Chk1-dependent pathway in vitro. APOBEC3B activation can be attenuated through repression of oncogenic signalling, small molecule inhibition of receptor tyrosine kinase signalling and alleviation of replication stress through nucleoside supplementation.

CONCLUSION

These data link oncogene, loss of tumour suppressor gene and drug-induced replication stress with APOBEC3B activity, providing new insights into how cytidine deaminase-induced mutagenesis might be activated in tumourigenesis and limited therapeutically.

摘要

背景

胞嘧啶脱氨酶APOBEC3家族在多种癌症类型中使癌症基因组发生突变。尽管许多研究已通过下一代测序记录了APOBEC3活性的下游效应,但其上游调控机制仍知之甚少。在本研究中,我们试图确定APOBEC3表达和激活的分子基础。

结果

HER2扩增和PTEN缺失在体外促进DNA复制应激和APOBEC3B活性,且与体内APOBEC3诱变相关。富含HER2的乳腺癌在体内显示出复制应激相关DNA损伤水平升高的证据。通过阿非科林、吉西他滨、喜树碱或羟基脲暴露进行化学和细胞毒性诱导的复制应激,在体外通过ATR/Chk1依赖性途径激活APOBEC3B的转录。通过抑制致癌信号传导、小分子抑制受体酪氨酸激酶信号传导以及通过核苷补充减轻复制应激,可以减弱APOBEC3B的激活。

结论

这些数据将癌基因、肿瘤抑制基因缺失和药物诱导的复制应激与APOBEC3B活性联系起来,为胞嘧啶脱氨酶诱导的诱变在肿瘤发生过程中如何被激活以及如何在治疗上受到限制提供了新的见解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aeaf/5025597/09e3d4820dc5/13059_2016_1042_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验